ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

High-risk and moderate-risk factors for developing preeclampsia

High-risk and moderate-risk factors for developing preeclampsia
  ACOG/SMFM/USPSTF[1] NICE[2] ISSHP[3]
High-risk factors
History of hypertensive disease in a previous pregnancy   X  
History of preeclampsia in a previous pregnancy X   X
Chronic hypertension X X X
Pregestational type 1/type 2 diabetes X X X
Chronic kidney disease X X X
Autoimmune disease (SLE or APS) X X X
Multifetal pregnancy X    
Prepregnancy BMI >30 kg/m2     X
Assisted reproductive technology     X
Combinations of multiple moderate risk factors X    
Moderate risk factors
Nulliparity X X X
First-degree relative with preeclampsia X X  
Multifetal pregnancy   X X
>10-year pregnancy interval X X  
BMI >30 kg/m2 X    
BMI >35 kg/m2 at first prenatal visit   X  
Age ≥35 years X    
Age >40 years   X X
Black race (as a proxy for underlying racism) X    
Lower income X    
IVF X    
Personal history factors (eg, low birth weight or small for gestational age, previous adverse pregnancy outcome) X    
Abruption, stillbirth, or fetal growth restriction in a previous pregnancy     X
Patients are considered at increased risk for developing preeclampsia when ≥1 high-risk factors or ≥2 moderate-risk factors are identified. Low-dose aspirin prophylaxis is initiated ideally at 12 to 16 weeks of gestation to reduce this risk.
ACOG: American College of Obstetricians and Gynecologists; USPSTF: US Preventive Services Task Force; SMFM: Society for Maternal-Fetal Medicine; NICE: National Institute for Health and Care Excellence; ISSHP: International Society for the Study of Hypertension in Pregnancy; SLE: systemic lupus erythematosus; APS: antiphospholipid syndrome; BMI: body mass index; IVF: in vitro fertilization.
References:
  1. American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine. Low-dose aspirin use for the prevention of preeclampsia and related morbidity and mortality [Practice Advisory]; 2021. (Reaffirmed October 2022.)
  2. National Institute for Health and Care Excellence. Hypertension in pregnancy: Diagnosis and management. NICE guideline No. 133; 2019:1.
  3. Magee LA, Brown MA, Hall DR, et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens 2022; 27:148.
Graphic 142323 Version 2.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟